Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Safe Supply Announces Signing of Definitive Agreement to Acquire Drug Lab 118 (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Healthcare Biotechnology Medical Instruments & Supplies
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Spectral Medical Inc > Summarizing the week
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(762)
•••
Comment by mercedesmanon Feb 24, 2024 11:04am
126 Views
Post# 35897137

RE:RE:RE:RE:RE:RE:Summarizing the week

RE:RE:RE:RE:RE:RE:Summarizing the week

Oh sorry. I thought you meant the news and follow-up call 

I have compared the old presentation to the new. 

looking quickly at slide 11, it seems to me we've known this for a month. It's like extra insurance in case for some reason the RCT in an of itself, without considering the Bayesian analysis, fails. 

Not sure how it could given past references to " exceeding expectations" and now perhaps an even lower threshold. However one has to admit that the paper lacks the appearance of independence. 

JL Vincent always said that solutions for afflictions like Sepsis could not be proven/ developed with 28-day mortality RCT's.   That was before he thought through targeted/precision medicine in order to get over the homogeneity issue. He will be proven wrong within 12 months. Thankfully for future sepsis sufferers. 


MM 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities